Is the measurement of sarcopenia associated with oncological disease in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

被引:1
|
作者
Siu, Adrian Hang Yue [1 ,2 ]
Holyland, Matthew [1 ]
Carey, Sharon [1 ,2 ]
Steffens, Daniel [1 ,2 ]
Ansari, Nabila [1 ,2 ,3 ,4 ]
Koh, Cherry E. [1 ,2 ,3 ,4 ]
机构
[1] Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, Camperdown, NSW, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, RPA Inst Acad Surg, Sydney, NSW, Australia
关键词
cytoreduction surgical procedures; hyperthermic intraperitoneal chemotherapy; peritoneal neoplasms; sarcopenia; OUTCOMES; COMPLICATIONS;
D O I
10.1111/ans.18645
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundPeritoneal malignancies are challenging cancers to manage. While cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC), may offer a cure, it is a radical procedure associated with significant morbidity. Pre-emptive identification of deconditioned patients for optimization may mitigate surgical risk. However, the difficulty lies in identifying a cost-effective predictive tool. Recently, there has been interest in sarcopenia, which may occur due to malignancy. The purpose of this study was to assess the utility of sarcopenia at predicting post-operative outcomes. MethodsA quaternary-centre retrospective study of CRS and HIPEC patients (2017-2020), were conducted to determine the association between pre-operative sarcopenia on oncological (peritoneal carcinomatosis index (PCI)) and surgical outcomes (complications). Sarcopenia from lumbar CT-images were measured using Slice-o-matic (TM). Statistical differences were analysed using Mann-Whitney U and Chi-squared test. ResultsCohort analysis (n=94) found 40% had sarcopenia, majority were female (53.2%), and average age of 55years. The major pathologies was colorectal cancer (n=39, 41.5%), appendix adenocarcinoma (n=21, 22.3%), and pseudomyxoma peritonei (PMP) (n=19, 20.2%). Sarcopenia was associated with decreased weight, 72.7 versus 82.2kg (P=0.014) and shorter survival, 1.4 versus 2.1years (95% CI, 1.09-3.05, P=0.032). Median PCI (excluding PMP) was 11 (6-18) and median PCI (only PMP) was 25 (11-32). Post-operatively, sarcopenia patients experienced more complications (72.5% vs. 64.8%, P=0.001). ConclusionPre-emptive identification of sarcopenia may be a useful prognostic indicator and predictor of post-operative outcomes in CRS and HIPEC. For oncological patients, sarcopenia may be an indicator of patients requiring targeted pre-operative rehabilitation, or advanced disease requiring further treatment.
引用
收藏
页码:2186 / 2191
页数:6
相关论文
共 50 条
  • [21] Decision Regret in Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Graves, Alexander
    Sadjadi, Javid
    Kosich, Mikaela
    Ward, Erin
    Sood, Divya
    Fahy, Bridget
    Pankratz, Shane
    Mishra, Shiraz I.
    Greenbaum, Alissa
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (12) : 7978 - 7986
  • [22] Palliative Care and Characterization of Symptoms in Patients Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy
    Sneider, Abigail P.
    Dhiman, Ankit
    Sood, Divya
    Ong, Cecilia
    Tun, Sandy
    Malec, Monica
    Levine, Stacie
    Turaga, Kiran K.
    Eng, Oliver S.
    JOURNAL OF SURGICAL RESEARCH, 2023, 283 : 1154 - 1160
  • [23] A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Lanuke, Kathryn
    Mack, Lloyd A.
    Temple, Walley J.
    CANADIAN JOURNAL OF SURGERY, 2009, 52 (01) : 18 - 22
  • [24] Evaluation of cisplatin plasma levels in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Fleres, Francesco
    Saladino, Edoardo
    Catanoso, Rosaria
    Arcoraci, Vincenzo
    Mandolfino, Tommaso
    Cucinotta, Eugenio
    Macri, Antonio
    ACTA CHIRURGICA BELGICA, 2016, 116 (01) : 19 - 22
  • [25] Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy
    Bhagwandin, S.
    Naffouje, S.
    Salti, G.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) : 2573 - 2577
  • [26] Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Wong, Evelyn Y. T.
    Tan, Grace H. C.
    Kumar, Mrinal
    Teo, Melissa C. C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (02) : E38 - E46
  • [27] Impact of BRAF and KRAS mutation on oncological outcomes in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Flood, Michael
    Waters, Peadar
    Ramsay, Robert
    Michael, Michael
    Tie, Jeanne
    Heriot, Alexander
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 121 - 122
  • [28] Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center
    L. Graziosi
    E. Marino
    V. De Angelis
    A. Rebonato
    A. Donini
    World Journal of Surgical Oncology, 14
  • [29] Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center
    Graziosi, L.
    Marino, E.
    De Angelis, V.
    Rebonato, A.
    Donini, A.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14 : 1 - 9
  • [30] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease
    Jiménez W.V.
    Bayón L.G.
    García-Sabrido J.L.
    Moreno S.G.
    Clinical and Translational Oncology, 2010, 12 (12) : 794 - 804